SPEECH - Dr. Dennis J. Slamon at Revlon�s Annual Philanthropic Luncheon

In the past two years, a new therapy for breast cancer has been developed, targeting the largest segment of breast cancer cases. This therapy, initially not used for breast cancer, has received FDA approval, significantly improving progression-free survival rates. The speaker expresses gratitude to supporters and emphasizes ongoing research efforts to continue making progress in breast cancer treatment.

What percentage of breast cancer cases does the new therapy target?

• 60 to 65 percent

• 70 to 75 percent

• 30 to 35 percent

• 20 to 25 percent

What was the outcome of the FDA's review of the new breast cancer treatment?

• It was delayed for further testing.

• It was approved with conditions.

• It was rejected due to insufficient data.

• It was approved in record time.

How did the new treatment affect progression-free survival for patients?

• It tripled the progression-free survival.

• It had no significant effect.

• It doubled the progression-free survival.

• It reduced the progression-free survival.

Who are some of the key supporters thanked for their contributions?

• Ronald and Revlon

• The FDA and NIH

• The World Health Organization

• The American Cancer Society

What is the focus of the ongoing research efforts mentioned in the final section?

• Focusing solely on HER2 positive breast cancer

• Stopping all current research

• Continuing to make progress for all women

• Developing a vaccine for breast cancer